Details to give your doctor
Signatera CRC HCP brochure
An overview of Signatera, the personalized and tumor-informed ctDNA monitoring and MRD assessment test.
Scientific rationale White Paper
A personalized, tumor-informed approach to detect molecular residual disease with high sensitivity and specificity. Design and analytical validation of Signatera, the first ctDNA assay custom-built for detecting MRD and assessing treatment response. View the file here.
Signatera CRC case studies
Questions about Signatera? Email [email protected] or call +1.650.489.9050